Abstract 1343
Background
Inhibition of vascular endothelial growth factor (VEGF) has shown antiangiogenic effects and immunomodulatory effects through enhancing tumor infiltration of immune cells in advanced renal cell carcinoma (RCC). Combination of checkpoint inhibitors with targeted therapy has synergistic antitumor activities and recent studies have demonstrated survival benefits. Yet, there are notable safety concerns. We conducted a systematic review and meta-analysis of randomized controlled trials (RCT) to determine the risk of treatment-related adverse events (TRAE) and treatment discontinuation due to TRAE.
Methods
PUBMED, MEDLINE, EMBASE databases and meeting abstracts from inception through March 2019 were queried. RCTs utilizing upfront checkpoint inhibitors combination therapy in patients with advanced RCC were incorporated. The primary meta- analytic approach was a random effects model using the Mantel-Haenszel (MH) method. It was used to calculate the estimated pooled risk ratio (RR) with 95% confidence interval (CI).
Results
4 phase III RCTs including 3758 patients with advanced RCC were eligible. The study arm used nivolumab+ ipilimumab, pembrolizumab+ axitinib, avelumab+ axitinib or atezolizumab+ bevacizumab while control arm utilized sunitinib. The randomization ratio was 1:1 in all studies. The pooled RR of any-grade TRAE was significant at 0.97 (95% CI: 0.95 –0.99, P = 0.007) and RR of high-grade TRAE was 0.88 (95% CI: 0.72 –1.09, P = 0.24). Treatment discontinuation due to TRAE was reported in 314 (16.84%) vs 200 (10.75%) in control group with RR of 1.43 (95% CI: 0.79 –2.57, P = 0.23). Treatment-related deaths were noted in 20 (1.07%) in study arm vs 13 (0.70%) in control arm. The pooled RR was not significant at 1.57 (95% CI: 0.62 –4.01, P = 0.34).
Conclusions
The risk of developing any-grade TRAE was reduced in upfront checkpoint inhibitors combination arm compared to standard sunitinib group, favoring combination therapy. Moreover, no increase in the risk of treatment related deaths as well treatment discontinuation due to TRAE was noted in the study arm.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kyaw Zin Thein.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5520 - Patient’s Usability Test results of a CINV Diary Application For Smartphones
Presenter: Paz Fernandez
Session: Poster Display session 3
Resources:
Abstract
2323 - Colorectal Telephone Assessment Pathway (CTAP) - A viable means of shortening time to a definitive diagnosis of Colorectal Cancer (CRC)
Presenter: Harriet Watson
Session: Poster Display session 3
Resources:
Abstract
6119 - Cancer Nursing and Social Media: Capturing the Zeitgeist
Presenter: Mark Foulkes
Session: Poster Display session 3
Resources:
Abstract
1776 - Examination of mobile applications on breast cancer
Presenter: AYDANUR AYDIN
Session: Poster Display session 3
Resources:
Abstract
4128 - E-health effectiveness to increase patient adherence for immunotherapy; a cost-benefit study.
Presenter: Maria José Dias
Session: Poster Display session 3
Resources:
Abstract
3219 - Experiences of internet-based stepped care among individuals with recently diagnosed cancer and symptoms of anxiety and/or depression
Presenter: Anna Hauffman
Session: Poster Display session 3
Resources:
Abstract
5010 - What do cancer patients know about their immunotherapy treatment?
Presenter: Mónica Arellano
Session: Poster Display session 3
Resources:
Abstract
4503 - Prospective Comparison of Travel Burden, Cost and Time to Obtain Tumor Board Treatment Plan Through In-Person Visits vs. an AI Enabled Health Technology (N=1803)
Presenter: Rajendra Badwe
Session: Poster Display session 3
Resources:
Abstract
4123 - Cancer care through the fire and flames: 3-year experience in the utilisation of electronic consultation and referral system at the Red Zone in Southern Thailand
Presenter: Nanthiya Rattanakhot
Session: Poster Display session 3
Resources:
Abstract
2087 - The effect of e-mobile education on the quality of life in women with breast cancer
Presenter: Derya ÇInar
Session: Poster Display session 3
Resources:
Abstract